Clinical trial · Interventional
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion: a Randomized Controlled Trial Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is prospective randomized control trial study. The aim of this study is to evaluate the efficacy of Iodopovidone solution for pleurodesis in palliative malignant pleural effusion (MPE) patients comparing to Talc. All adult patients who diagnosed MPE by cytology regardless primary tumor between December 1, 2015 and November 29, 2016 at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand will be enrolled in this study. The inform and consent will be applied in all patients before treatment. Patients will be randomized to two groups; Iodopovidone group (intervention group) and Talc group (control group)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Iodopovidone solution | Drug | — | UNRESOLVED |
| Talc | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Iodopovidone group
- description
- Patients who will be randomized for using iodopovidone solution for pleurodesis.
- interventionNames
- Drug: Iodopovidone solution
- type
- ACTIVE_COMPARATOR
- label
- Talc group
- description
- Patients who will be randomized for using Talc for pleurodesis.
- interventionNames
- Drug: Talc
Primary outcomes (1)
- measure
- Success of treatment
- timeFrame
- 7 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. All MPE proved by cytology 2. After pleural effusion was released by chest tube drainage, lung was fully expanded Exclusion Criteria: 1. Patients who have Karnofsky performance state ≤ 40 2. History of iodine allergy 3. History of morphine allergy 4. Abnormal thyroid hormones.
References
Publications (0)
Data not yet available